$2.61 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 93 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HSGX | Exit | HISTOGENICS CORP | $0 | – | -296,099 | -100.0% | -0.00% | – |
| MLNT | Exit | MELINTA THERAPEUTICS INC | $0 | – | -333,902 | -100.0% | -0.01% | – |
| RMED | Exit | RA MED SYS INC | $0 | – | -108,400 | -100.0% | -0.04% | – |
| MNKD | Exit | MANNKIND CORP | $0 | – | -943,298 | -100.0% | -0.04% | – |
| VYGR | Exit | VOYAGER THERAPEUTICS INC | $0 | – | -117,647 | -100.0% | -0.04% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -419,000 | -100.0% | -0.05% | – |
| NVTRQ | Exit | NUVECTRA CORP | $0 | – | -129,000 | -100.0% | -0.08% | – |
| BIOS | Exit | BIOSCRIP INC | $0 | – | -767,000 | -100.0% | -0.11% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -475,000 | -100.0% | -0.18% | – |
| LIVN | Exit | LIVANOVA PLC | $0 | – | -71,500 | -100.0% | -0.26% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCspon ads | $0 | – | -235,576 | -100.0% | -0.31% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -129,000 | -100.0% | -0.33% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -622,548 | -100.0% | -0.38% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -1,343,181 | -100.0% | -0.42% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -109,117 | -100.0% | -0.42% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -621,000 | -100.0% | -0.64% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -180,000 | -100.0% | -0.96% | – |
| CVS | Exit | CVS HEALTH CORPcall | $0 | – | -566,800 | -100.0% | -1.49% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 33 | Q2 2024 | 3.3% |
| BIOCRYST PHARMACEUTICALS INC | 32 | Q2 2024 | 2.2% |
| MOLINA HEALTHCARE INC | 27 | Q2 2024 | 1.7% |
| BROOKDALE SR LIVING INC | 26 | Q2 2024 | 2.2% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| DECIPHERA PHARMACEUTICALS IN | 24 | Q1 2024 | 2.0% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-17 |
| 3 | 2024-09-12 |
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-07-17 |
| 4 | 2024-07-15 |
| 4 | 2024-07-11 |
| 4 | 2024-06-14 |
| 4 | 2024-06-03 |
| 13F-HR | 2024-05-15 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.